NewAmsterdam Pharma Company N.V.
NAMS
$15.12
$0.221.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.77M | 29.11M | 2.28M | 1.40M | 803.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.77M | 29.11M | 2.28M | 1.40M | 803.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 12.77M | 29.11M | 2.28M | 1.40M | 803.00K |
| SG&A Expenses | 21.11M | 18.41M | 16.48M | 14.45M | 10.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.00M | 54.11M | 54.85M | 56.88M | 51.88M |
| Operating Income | -43.23M | -25.00M | -52.58M | -55.48M | -51.07M |
| Income Before Tax | -92.18M | -16.65M | -39.01M | -93.77M | -49.47M |
| Income Tax Expenses | 0.00 | -1.00K | -- | -- | 27.00K |
| Earnings from Continuing Operations | -92.18M | -16.65M | -39.01M | -93.77M | -49.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.18M | -16.65M | -39.01M | -93.77M | -49.50M |
| EBIT | -43.23M | -25.00M | -52.58M | -55.48M | -51.07M |
| EBITDA | -43.18M | -24.98M | -52.56M | -55.47M | -51.06M |
| EPS Basic | -0.93 | -0.18 | -0.41 | -2.12 | -0.60 |
| Normalized Basic EPS | -0.54 | -0.10 | -0.32 | -1.05 | -0.40 |
| EPS Diluted | -0.93 | -0.18 | -0.41 | -2.12 | -0.60 |
| Normalized Diluted EPS | -0.54 | -0.10 | -0.32 | -1.05 | -0.40 |
| Average Basic Shares Outstanding | 99.43M | 94.75M | 94.71M | 176.84M | 82.47M |
| Average Diluted Shares Outstanding | 99.43M | 94.75M | 94.71M | 176.84M | 82.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
